Pilian

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pilian

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Oral tablet, Oral solution, Syrup
Pharmacological class First-Generation Antihistamine, Antiserotonergic Agent
Common use Relief of allergic symptoms
Origin Synthetic compound

What Type of Medicine is Pilian?

Pilian is a prescription-only (Rx) pharmaceutical preparation whose active ingredient is cyproheptadine hydrochloride, a synthetic compound. It is formally classified as a first-generation antihistamine and belongs to the piperidine class of these agents. This pharmacological class is widely and historically clinically recognized for its efficacy in rapidly mitigating allergic reactions. Pilian's defining characteristic is its established dual mechanism of effect as both a potent, competitive histamine antagonist and a significant antiserotonergic agent, acting at the serotonin 5-HT2A receptor. This complex action is a distinguishing feature, differentiating it from newer, more selective antihistamines.

Composition, Forms, and General Purpose

The medication is a single-ingredient product, containing only cyproheptadine hydrochloride, and is intended for oral administration. It is supplied in multiple common dosage forms, notably the oral tablet and the less frequent oral solution or syrup, making it suitable for both adults and certain pediatric patients. By effectively blocking both histamine and serotonin pathways, the medicine's general therapeutic purpose is to serve as an antiallergic-antipruritic compound, aiming to relieve discomfort associated with various allergic conditions. The drug's capacity to cross the blood-brain barrier is associated with its well-known sedating effect, a key characteristic of the first-generation class.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Pilian?

Possible Side Effects and Safety Information

The safety profile of Pilian (cyproheptadine hydrochloride) reflects its classification as a first-generation antihistamine, with documented adverse reactions spanning several physiological systems as noted in government regulatory labeling.

Primary Adverse Reaction Patterns

The most frequently reported effects are generally categorized under the Central Nervous System (CNS). These commonly reported reactions include sedation, sleepiness (somnolence), dizziness, and disturbed coordination. These CNS effects are often noted to be transient, potentially subsiding after the first few days of continuous use. In the Metabolism and Nutrition Disorders classification, increased appetite and weight gain are also listed as common adverse reactions.

Systemic and Serious Safety Considerations

The medicine's safety profile includes potential effects across numerous System-Organ Classes (SOC), such as the cardiovascular, gastrointestinal, and hematologic systems. While rare, regulatory documents note the potential for serious adverse reactions, including specific forms of hepatic function abnormality (e.g., jaundice or hepatitis) and blood dyscrasias (e.g., agranulocytosis) associated with prolonged therapy.

Population-Specific Restrictions

Official labeling contains specific constraints concerning certain populations. The medicine is contraindicated for use in newborn or premature infants and in elderly, debilitated patients due to increased vulnerability to side effects such as sedation and hypotension. Caution is also advised when administering the drug to patients with pre-existing conditions sensitive to its anticholinergic properties, such as a history of increased intraocular pressure or cardiovascular disease.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Pilian addresses the serious and potentially life-threatening nature of overdose.

Documented Overdose Manifestations

An overdose is typically characterized by a combination of severe clinical signs, including:

  • Respiratory Depression: Slowed, shallow breathing, or difficulty breathing, which may progress to respiratory arrest.
  • CNS Depression: Profound somnolence, inability to respond, or progressing to a state of coma.
  • Circulatory Signs: Low blood pressure (hypotension) and a slowed heart rate (bradycardia).
  • Other Manifestations: Cold and clammy skin, or pinpoint pupils (miosis).

When to Seek Urgent Medical Help

Immediate medical attention is required. The official drug labeling instructs patients and caregivers to seek emergency medical help or call 911 (or equivalent local emergency number) immediately if any signs of respiratory depression, severe sedation, or unresponsiveness occur.

Management and Monitoring

The established procedure for managing a Pilian overdose is based on supportive care and the use of a reversal agent.

  • Antidote: A specific opioid antagonist (e.g., naloxone) is indicated for reversing clinically significant respiratory or circulatory depression.
  • Supportive Care: Immediate steps involve establishing a patent airway and providing controlled ventilation.
  • Observation: Continuous observation and monitoring of the patient's condition are necessary, as the effects of the drug may outlast the effects of the antidote, potentially leading to a recurrence of respiratory depression.

Accidental ingestion, especially by children, carries a high risk of fatal overdose.

Therapeutic Uses of Pilian

Pilian (cyproheptadine hydrochloride) is commonly used across domains where additional symptomatic support is needed, assisting with the management of symptoms related to physical discomfort and systemic imbalance. Its primary therapeutic applications span three distinct areas, offering supportive relief in situations marked by heightened patient distress.

The medication is applied in clinical settings that involve acute or unstable symptom patterns. Its uses involve the management of allergic symptoms (like seasonal and perennial rhinitis, urticaria, and pruritus), prophylaxis for certain recurrent vascular headaches such as migraine, and supportive care for appetite stimulation and associated weight gain.

For allergic and pruritic discomfort, Pilian helps address symptom clusters that may become intense or disruptive, such as generalized itching (pruritus) and the swelling of hives. It is commonly used when symptoms intensify and supportive relief is needed, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Pruritus and Migraine

Pilian is applied in addressing symptoms related to inflammatory or irritative states like intense itching, and supports the management of symptoms of increased neurological activity in the prophylactic care of recurrent headaches.

Regulatory References

  1. DailyMed official indications

Eligibility and Restrictions for Use

Pilian (cyproheptadine) is an antihistamine primarily used to treat various allergic conditions, including seasonal and perennial allergic rhinitis, conjunctivitis, urticaria (hives) and angioedema. It may also be used as adjunctive therapy in anaphylaxis management after initial treatment with epinephrine.

Who Can Use Pilian?

Pilian is generally indicated for use in adults and children aged two years and older for allergic symptoms. For children under two years old, the safety and efficacy of the medication have not been established. Use in pediatric patients is carefully managed due to the risk of central nervous system overstimulation.

Who Cannot Use Pilian (Contraindications)?

The medication is contraindicated in several specific situations. You must not take Pilian if you:

  • Are allergic to cyproheptadine or similar medications.
  • Are a newborn or premature infant.
  • Are breastfeeding, due to the potential for adverse effects on the nursing infant.
  • Have narrow-angle glaucoma.
  • Have a stenosing peptic ulcer or a pyloroduodenal obstruction (gut blockage).
  • Have symptomatic prostatic hypertrophy (enlarged prostate) or bladder neck obstruction (urination problems).
  • Are taking Monoamine Oxidase Inhibitors (MAOIs), as this can prolong and intensify the anticholinergic effects.
  • Are an elderly or debilitated patient, as they are at a higher risk of side effects like confusion and sedation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the product’s interaction profile primarily through pharmacodynamic reinforcement, which dictates specific restrictions on co-administration.

Classification Type Restriction or Interaction Outcome
Contraindicated Combination Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. MAOIs prolong and intensify the drug's anticholinergic effects.
Additive CNS Effects The medicine may cause additive effects when used with other Central Nervous System (CNS) depressants, including alcohol, hypnotics, sedatives, tranquilizers, and antianxiety agents.
Population Note Interaction outcomes related to CNS depression (dizziness, sedation, and hypotension) are more likely to occur in elderly patients

Official Interaction Statements:

  • The combination with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of intensifying anticholinergic effects.
  • Additive CNS depression may result from co-administration with alcohol and other CNS depressant medications.
  • The anti-serotonin activity of the drug may interfere with serotonin-enhancing anti-depressants (such as SSRIs), which may lead to the recurrence of depressive symptoms.

No timing-based separation rules or specific pharmacokinetic-enzyme (CYP) interactions are explicitly described in the high-level prescribing information. The interaction structure necessitates official caution regarding co-administration with numerous CNS-active products.

Mechanism of Action

How Pilian Works

Pilian exerts its action primarily as a non-selective antagonist at multiple neuroreceptor sites in both the central and peripheral nervous systems. The primary mechanism involves high-affinity competitive antagonism at histamine H1 receptors. This interaction modifies signal transduction within the histaminergic pathway, particularly affecting systems that control vascular permeability and sensory nerve activation.

A second significant domain is the antagonism of several serotonin 5-HT receptor subtypes, predominantly 5-HT2 A and 5-HT2 C. This modulation influences receptor systems located in the hypothalamus, which are associated with the regulation of energy balance and feeding behavior, altering the neurochemical signals related to feeding.

An auxiliary mechanism includes an inhibitory effect on muscarinic acetylcholine receptors. This action alters output signals from the parasympathetic nervous system, leading to a decrease in both glandular secretion and involuntary smooth muscle contraction.

Dosage and Administration Information

How Pilian is Used: Administration Guidelines

Administration of Pilian (cyproheptadine hydrochloride) is strictly limited to the oral route, available as a tablet or a liquid solution/syrup. The medication's usage protocol is structured around highly specific dosing requirements and recognized maximum limits.

Standard Dosing and Frequency

The dosage must be individualized based on the patient's need and response. For adults, the usual starting dose is 4 mg taken three times a day, typically in divided doses to ensure a consistent effect throughout the day. The total daily dosage for an adult must not exceed the maximum of 32 mg. The frequency is guided by the short duration of effect of a single dose, often requiring administration every four to six hours.

Population Initial Dose Maximum Daily Dose
Adults 4 mg 32 mg
Pediatric (7–14 yrs) 4 mg 16 mg
Pediatric (2–6 yrs) 2 mg 12 mg

Population-Specific Use

Pilian is not recommended for children under two years of age because safety and efficacy have not been established in this group. For pediatric patients aged 2 to 14 years, the total daily dose is divided and administered two or three times daily, with specific maximum limits based on age group. Dose selection for older adults should be initiated at the lower end of the usual range. Patients with documented renal impairment require lower doses and close monitoring, as the elimination of the compound is diminished.

Recent Clinical Evidence

Research evidence / Overview of studies for Pilian (Cyproheptadine)


Evidence from Studies on Allergic Symptoms and Hives

Pilian was studied for use in conditions that involve various allergic symptoms, such as chronic hives (urticaria) and rhinitis. The research explored how this medicine was evaluated in trials assessing short-term or episodic symptom patterns. These studies primarily employed short-term randomized controlled trial (RCT) designs and measured outcomes related to physical discomfort like sneezing and intense itching (pruritus).

Findings describe patterns observed in the studies regarding changes in outcomes linked to inflammatory or irritative states in the observed populations. Evidence contributes to understanding symptom patterns, particularly for chronic hives. However, certain limitations exist in the research base, as many of the foundational studies are older, and comparative evidence is lacking for large-scale, modern trials directly against more recent pharmacological options.


Evidence from Studies on Recurrent Headache Prophylaxis

Research was studied for Pilian's role in research exploring recurrent vascular headaches. Studies explored how the medicine affected outcomes describing episodic or acute changes, specifically focusing on the frequency and severity of headache attacks. The available evidence is based on systematic reviews, open-label studies, and some smaller RCTs.

The data show patterns related to the reduction in headache episodes in the observed populations, but findings were mixed regarding the level of impact, particularly when comparing outcomes across different study designs. Evidence quality varies across studies in this area, and subgroup findings are uncertain, as many reports are retrospective or open-label.


What is Still Uncertain About the Research

The research on Pilian is characterized by certain gaps and limitations. Sample sizes were modest in many of the trials conducted for headache research and appetite stimulation, which limits the ability to draw broad conclusions. Furthermore, there is limited information for long-term outcomes regarding how well any observed changes are sustained. Research is ongoing to provide further context, but the evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. Cyproheptadine: Drug Label and Regulatory Information
  2. Cyproheptadine - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

Frequently Asked Questions (FAQ)

Common questions about Pilian (FAQ)

Q: How quickly should I expect Pilian to start working for my symptoms?

A: Official information does not consistently state the exact onset time of the drug's effects. Regulatory information indicates the drug's action is short, which is why it requires frequent dosing to maintain a consistent effect. The exact time it begins to work for an individual is not explicitly stated.

Q: How long does the effect of one Pilian tablet usually last?

A: Due to the medication's short duration of action, it is typically administered multiple times a day—often two or three times, approximately every four to eight hours—to ensure continuous symptom relief. This short duration is why the medication may be administered in divided doses throughout the day.

Q: Can Pilian be taken for long-term management of chronic allergies?

A: Regulatory documents do not explicitly address the use of this drug for long-term management. Official labeling notes the potential for rare, serious side effects, such as blood dyscrasias or liver function abnormality, that have been associated with prolonged therapy. Research often focuses on short-term symptom patterns.

Q: Why does Pilian sometimes cause increased appetite or weight gain?

A: The mechanism of this medication involves activity at specific serotonin (5-HT) receptor subtypes. These receptors are located in areas of the brain, like the hypothalamus, that are associated with regulating energy balance and feeding behavior. This action can lead to increased appetite.

Q: Can Pilian interact with medications that cause sedation, like sleeping pills?

A: Yes, official warnings indicate that Pilian can cause additive Central Nervous System (CNS) effects. This risk occurs when it is used alongside other CNS depressants, which includes hypnotics, sedatives, tranquilizers, and antianxiety agents.

Q: Does Pilian have an anticholinergic effect, and what does that mean?

A: Yes, the drug has an anticholinergic effect, meaning it inhibits signals in the parasympathetic nervous system. This action can cause common side effects such as dry mouth, blurred vision, constipation, and difficulty urinating.

Q: Does Pilian affect stomach or bowel function, like causing constipation?

A: Official adverse reaction lists include constipation as a potential side effect of Pilian. The drug is also contraindicated for people with conditions that block the gut, such as a stenosing peptic ulcer or a pyloroduodenal obstruction.

Q: Does Pilian affect heart rate, and is this a concern?

A: Official warnings note that the drug is contraindicated in patients with cardiovascular disease. It has the potential to cause adverse effects like tachycardia (increased heart rate) and hypotension (low blood pressure), especially in older adults.

Q: Does Pilian cause dry mouth, and what helps with this symptom?

A: Dry mouth is a common anticholinergic side effect of this medication. This symptom is commonly managed by increasing water intake or using measures such as sugarless gum or hard candy, according to standard patient counseling.

Q: What vision-related side effects are possible with Pilian?

A: Possible side effects include visual disturbances such as blurred vision. Furthermore, the drug is formally contraindicated (should not be used) in patients who have narrow-angle glaucoma.

Q: Why does Pilian sometimes make it hard to urinate or empty the bladder?

A: This difficulty (urinary retention) is due to the drug's anticholinergic effects. It is a contraindication for individuals with pre-existing conditions that affect urination, such as symptomatic prostatic hypertrophy (enlarged prostate) or bladder neck obstruction.

Q: What should I do if I forget to take a dose of Pilian?

A: Official patient instructions describe a procedure for a missed dose, which typically involves taking the dose when remembered unless it is nearly time for the next dose. It is generally advised not to double the dose to catch up.

Q: Can Pilian affect my ability to concentrate or operate machinery?

A: Due to the potential for drowsiness, dizziness, and disturbed coordination, the official warning advises caution regarding driving or operating heavy machinery.

Q: What should I look out for if I'm taking Pilian that would signal a serious side effect?

A: Official patient information states that signs of a serious adverse reaction include difficulty urinating, vision problems, and severe nervousness or restlessness (especially in children). Any concerning symptoms should be relayed to a healthcare professional.

Q: Can Pilian be taken by people who have asthma or other breathing issues?

A: Official warnings indicate that the drug is generally contraindicated for use during an acute asthma attack. Caution is advised for patients who have a history of asthma or chronic lower respiratory disease.

Q: How long do common side effects like drowsiness typically last when starting Pilian?

A: Official labeling states that the most frequently reported Central Nervous System effects, such as drowsiness and sleepiness, are often transient. They may subside and lessen in intensity after the first few days of continuous treatment.

Q: How should Pilian be stored to maintain its effectiveness?

A: Official regulatory documents require Pilian tablets to be stored at Controlled Room Temperature, which is between 20 to 25 C (68 to 77 F). The oral solution or syrup formulations must also be stored with specific protection from light.

Q: What is the 'paradoxical excitement' side effect, especially in children?

A: Paradoxical excitement is an unusual reaction, often described as restlessness, nervousness, or excitability, that occurs instead of the usual sedating effect. This reaction has been noted in the official adverse reactions list, particularly in pediatric patients.

Q: Can Pilian cause confusion, especially in older patients?

A: Yes, official warnings indicate that elderly or debilitated patients are at a higher risk of adverse reactions, including confusion, dizziness, and sedation. For this reason, use in this population is often cautioned or contraindicated.

Q: If I have a history of seizures, is Pilian still safe to take?

A: Official information indicates that convulsions (seizures) have been reported by some people taking the drug, and this may be more common in children. Information about this risk is available in the regulatory documentation.

Q: Can Pilian cause a jittery feeling instead of drowsiness in some people?

A: Yes, the official adverse reactions list includes the potential for excitement, restlessness, or a jittery feeling. This is a form of paradoxical reaction that can occur, especially in children, instead of the expected sedation.

Q: Are there specific food interactions to be aware of when taking Pilian?

A: Official high-level patient instructions typically do not note specific food interactions for this drug. Unless a healthcare provider gives explicit dietary instructions, patients can usually continue their normal diet while taking the medication.

Q: Can Pilian be used to relieve persistent itchiness from skin conditions?

A: Yes, regulatory documents list the drug as being indicated for the symptomatic relief of pruritus (itching). This relief is for the itching associated with various allergic conditions.

Q: Is Pilian safe to take while pregnant?

A: The oral tablet form of the drug is classified under Pregnancy Category B. This means that animal reproduction studies generally have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies conducted in pregnant women.

How should Pilian be stored and disposed of?

Storage Requirements

Official regulatory documents require that Pilian tablets be stored at Controlled Room Temperature, which is defined as 20 to 25 C (68 to 77 F). The oral solution and syrup formulations must be stored with protection from light. Tablets must be dispensed in a well-closed container that includes a child-resistant closure.

Child-Safety and Handling

All forms of the medication must be stored out of the reach of children to prevent accidental ingestion. Storage environments that exceed or fall below the required temperature range should be avoided.

Disposal

Specific disposal instructions are not detailed in the product labeling. Unused or expired Pilian should be discarded according to federal and local regulations, such as by participating in a drug take-back program or following the general FDA guidelines for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pilian found in:

A-Z Index: